A clinical study on MRI combined with bone marrow protection and intensity-modulated radiotherapy to alleviate bone marrow suppression of neoadjuvant radiotherapy and chemotherapy for rectal cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030822

Enrollment

Unknown

Registered

2020-03-15

Start date

2020-04-01

Completion date

Unknown

Last updated

2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal cancer

Interventions

MR group:MRI-defined pelvic active bone marrow

CT group:bone marrow-cavity contour on CT images

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-75 years; 2. With histologically proved rectal adenocarcinoma located = 4.0 x 10^9/L, absolute neutrophil counts (ANC) >= 2.0 x 10^9/L, hemoglobin > 120 g/L, platelet counts >= 100 x 10^9/L; 7. Patients who will sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with acute and chronic infection, rheumatism, immune system or hematopoietic dysfunction; 2. Pregnant or lactating women; 3. With disorders of mental illness or mental retardation; 4. Patients participating in other clinical studies or drug experiments at the same time.

Design outcomes

Primary

Measure	Time frame
hematologic toxicity;	—

Countries

China

Contacts

Public ContactYijun Wang

Jiangsu Hospital of Traditional Chinese Medicine

elevenlati@foxmail.com+86 15195959608

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026